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 Background: Most recurrences in women with breast cancer 
receiving 5 years of adjuvant tamoxifen occur after 5 years. 
The MA.17 trial, which was designed to determine whether 
extended adjuvant therapy with the aromatase inhibitor 
 letrozole after tamoxifen reduces the risk of such late recur-
rences, was stopped early after an interim analysis showed 
that letrozole improved disease-free survival. This report 
presents updated fi ndings from the trial.  Methods: Postmeno-
pausal women completing 5 years of tamoxifen treatment 
were randomly assigned to a planned 5 years of letrozole 
( n = 2593) or placebo ( n = 2594). The primary endpoint was 
 disease-free survival (DFS); secondary endpoints included 
distant disease-free survival, overall survival, incidence of 
contralateral tumors, and toxic effects. Survival was exam-
ined using Kaplan – Meier analysis and log-rank tests. Planned 
subgroup analyses included those by axillary lymph node 
 status. All statistical tests were two-sided.  Results: After a 
 median follow-up of 30 months (range = 1.5 – 61.4 months), 
women in the letrozole arm had statistically signifi cantly 
 better DFS and distant DFS than women in the placebo arm 
(DFS: hazard ratio [HR] for recurrence or contralateral 
breast cancer = 0.58, 95% confi dence interval [CI] = 0.45 to 
0.76;  P <.001; distant DFS: HR = 0.60, 95% CI = 0.43 to 0.84; 
 P = .002). Overall survival was the same in both arms (HR for 
death from any cause = 0.82, 95% CI = 0.57 to 1.19;  P = .3). 
However, among lymph node – positive patients, overall sur-
vival was statistically signifi cantly improved with letrozole 
(HR = 0.61, 95% CI = 0.38 to 0.98;  P = .04). The incidence of 
contralateral breast cancer was lower in women receiving 
 letrozole, but the difference was not statistically signifi cant. 
Women receiving letrozole experienced more hormonally 
 related side effects than those receiving placebo, but the inci-
dences of bone fractures and cardiovascular events were the 
same.  Conclusion: Letrozole after tamoxifen is well-tolerated 
and improves both disease-free and distant disease – free 
 survival but not overall survival, except in node-positive 
 patients. [J Natl Cancer Inst 2005;97:1262–71]
 Estrogen is intimately linked to the pathogenesis of breast 
cancer  ( 1 ) . Tamoxifen antagonizes growth of estrogen-dependent 
breast cancer, and 5 years of tamoxifen has been the standard 
adjuvant endocrine therapy for women with estrogen receptor 
(ER) – positive breast cancer  ( 2 , 3 ) . Improvements in disease-free 
survival and overall survival from 5 years of tamoxifen continue 
up to at least 15 years following diagnosis  ( 4 ) . Extending  adjuvant 
tamoxifen for more than 5 years has not been shown to further 
improve survival  ( 5 , 6 ) , and in 1995 the U.S. National Cancer 
Institute issued a clinical directive to limit adjuvant tamoxifen 
use to 5 years  ( 7 ) . 
 Despite these benefi ts, women who have been treated with 
5 years of tamoxifen subsequently experience substantial rates 
of both new primary tumors and relapses at all sites, the latter at 
a frequency related to nodal status at presentation, and these 
events are associated with ongoing mortality  ( 8 ) . Indeed, most 
 recurrences in women receiving 5 years of adjuvant tamoxifen 
treatment for breast cancer occur after 5 years. The MA.17 trial 
was designed to determine whether the aromatase inhibitor 
 letrozole, given after 5 years of tamoxifen, could further  decrease 
the risk of late relapse and improve survival. The hypothesis was 
that, if the micrometastatic cells that are the source of subse-
quent breast cancer in tamoxifen-treated women become resis-
tant to or dependent on tamoxifen, then these cells might be 
particularly  vulnerable to aromatase inhibition  ( 9 – 16 ) . The choice 
of letrozole was supported by the fi ndings of its substantial ben-
efi ts in preclinical models  ( 17 ) and in women with  metastatic 
breast  cancer, including those with disease progression on 
tamoxifen  ( 18 , 19 ) . 
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 The MA.17 trial began accruing breast cancer patients who 
had been treated with 5 years of tamoxifen in August 1998. The 
targeted sample size, 4800, was reached at the end of May 
2002. However, the study stayed open for several more months 
in  selected centers to allow recruitment to a bone density and 
bone biomarker substudy to meet its target accrual. Enrollment 
to MA.17 was closed on September 4, 2002, with 5187 patients 
randomly assigned to 5 years of letrozole or placebo. However, 
the study was stopped by the Data Safety Monitoring Commit-
tee (DSMC) of the National Cancer Institute of Canada  Clinical 
Trials Group (NCIC CTG) approximately 1 year earlier than 
planned, in October 2003, after the fi rst protocol – prespecifi ed 
interim effi cacy analysis. The DSMC was presented with the 
results of the interim analysis in August 2003, at a median 
 follow-up of 2.4 years, after 207 events had occurred; it  revealed 
a 6% difference in 4-year disease-free survival, which increased 
from 87% in the placebo arm to 93% in the letrozole arm 
( P <.001). This difference exceeded the predefi ned O’Brien –
 Fleming stopping boundary. Prespecifi ed subset analyses were 
not planned for the fi rst interim analysis, but an unplanned 
analysis demonstrated that the improvement in disease-free 
survival with letrozole was statistically signifi cant in both 
lymph node – positive and lymph node – negative patients. All 
study participants were notifi ed of the results, and those who 
had been taking placebo were offered the option to cross over 
to letrozole treatment. 
 Because of the nature of interim analyses, our fi rst report of 
the MA.17 trial  ( 20 ) included only the effi cacy results based on 
events observed before August 19, 2003, and toxic effects docu-
mented before February 28, 2003. In this article, we present the 
fi nal effi cacy and toxicity results, including all preplanned subset 
analyses, based on all events that occurred up to the unblinding 
of study participants in October 2003. 
 S UBJECTS AND M ETHODS 
 Patients and Study Design 
 The MA.17 trial was a randomized, double-blind, placebo-
controlled trial of letrozole (2.5 mg orally daily) versus placebo 
(orally daily), given for a period of 5 years. Criteria for eligibility 
in the trial included: previous adjuvant tamoxifen therapy lasting 
4.5 – 6 years; histologically confi rmed primary breast cancer; a 
tumor that was positive for estrogen receptor (ER), progesterone 
receptor (PR), or both (defi ned by a level of 10 fmol/mg protein 
or a positive result on immunohistochemical analysis of ER or 
PR); discontinuation of tamoxifen therapy less than 3 months 
 before enrollment; an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0, 1, or 2 (scored on a scale of 0 
to 4, with lower scores indicating better function); a life expec-
tancy of more than 5 years; and postmenopausal status. Women 
were defi ned as being postmenopausal if they were at least 50 
years of age at the start of adjuvant tamoxifen therapy, were 
younger than 50 years at the start of tamoxifen therapy but post-
menopausal at the initiation of tamoxifen therapy, were younger 
than 50 years at the start of tamoxifen therapy but had undergone 
bilateral oophorectomy, were premenopausal and younger than 
50 years of age at the start of tamoxifen therapy but became 
amenorrheic during chemotherapy or treatment with tamoxifen, 
or were any age but had postmenopausal levels of luteinizing 
hormone or follicle-stimulating hormone prior to study enroll-
ment.  Women with unknown hormone receptor status were eli-
gible, provided an effort was made to determine the receptor 
status of the primary tumor. Patients were stratifi ed according to 
tumor hormone receptor status (ER- and/or PR-positive or un-
known), lymph node status (negative, positive, or unknown), and 
prior adjuvant chemotherapy (yes or no). The MA.17 trial was 
led by the NCIC CTG and included the North American Breast 
Intergroup and the Breast International Group. Each institution’s 
ethics review board approved the study protocol. All patients 
gave written informed consent. Data were received, reviewed, 
and analyzed by NCIC CTG. 
 Statistical Analysis 
 The primary endpoint of MA.17 was disease-free survival, 
which was defi ned as time from randomization to the earliest 
 recurrence of breast cancer (breast, chest wall, regional nodes, or 
distant metastasis) or a contralateral new primary breast cancer. 
Secondary endpoints defi ned in the original protocol included 
overall survival, calculated as the time from randomization until 
death from any cause; annual incidence rate of contralateral 
breast cancer; long-term safety and tolerability; and overall and 
menopause-specifi c quality of life. Distant disease – free survival 
was a secondary endpoint defi ned in the fi nal analysis; it was 
calculated as the time from random assignment until the fi rst 
 observation of distant metastasis. 
 The survival curves for all time-to-event endpoints were 
 estimated by the Kaplan – Meier method  ( 21 ) and compared 
 primarily with a stratifi ed log-rank test adjusting for the three 
stratifi cation factors (hormone receptor status, lymph node 
 status, and prior adjuvant chemotherapy). The hazard ratios 
(HRs) between treatment groups for these endpoints and asso-
ciated 95% confi dence intervals (CIs) were calculated from the 
stratifi ed Cox proportional hazards model with a single treat-
ment covariate and adjustment for the same three stratifi cation 
factors. For the primary endpoint, exploratory multivariable 
analyses were performed with the same stratifi ed Cox propor-
tional hazards model but that included as covariates treatment 
and the other two potential prognostic factors — menopausal 
status at the start of tamoxifen treatment ( ≥ 50 years of age at 
the start of treatment with adjuvant tamoxifen versus other 
 defi nitions of menopause) and duration of tamoxifen treatment 
( ≤ 5 years versus >5 years) — to verify the impact of the three 
stratifi cation factors and these two additional potential prog-
nostic factors on the treatment  effect. The proportional hazards 
assumption in the Cox model was verifi ed by the Grambsch –
 Therneau test  ( 22 ) . 
 In an analysis plan prepared before the interim analysis was 
conducted, it was specifi ed that the analyses for disease-free and 
overall survival would be presented for the subgroups defi ned by 
the levels of the three stratifi cation factors and the two additional 
potential prognostic factors mentioned above for the exploratory 
multivariable analysis. 
 A total of 4800 patients were needed to permit the detection of 
a hazard rate of 0.78, which corresponds to a 2.5% improvement 
in 4-year disease-free survival with letrozole, from 88% to 90.5%, 
with 80% power and a two-sided test of signifi cance at the 
5% level. Two interim analyses were scheduled when 171 and 
342 events were observed. Lan – DeMets alpha spending function 
with conventional O’Brien – Fleming stopping rules  ( 23 ) were 
specifi ed a priori for interim monitoring. 
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 All available events occurring on or before October 9, 2003, 
were analyzed for this update. All patients, apart from 17 (all of the 
patients from one center) who were excluded due to  “ good clinical 
practice ” violations, were included in all the analyses of pretreat-
ment characteristics and of survival and breast cancer outcomes. 
Safety and study drug exposure were analyzed on all patients who 
received at least one dose of study medication.  Statistical Analysis 
System (SAS) version 8 was used in all the analyses except 
the  verifi cation of proportional hazard  assumptions, which used 
S-Plus version 5. All  P values were two-sided. 
 R ESULTS 
 Study Population 
 A total of 5187 patients were randomly assigned to the letro-
zole ( n = 2593) and placebo ( n = 2594) arms ( Fig. 1 ). Because of 
noncompliance with  “ good clinical practice ” guidelines, 17 
 patients (10 in the letrozole arm and 7 in the placebo arm) were 
excluded from all analyses, leaving 5170 patients (2583 in the 
letrozole arm and 2587 in the placebo arm). All other patients 
were included in the analyses of time-to-event endpoints based on 
the treatment groups to which they had been randomly  assigned. 
Among the randomly assigned patients, 50 (25 receiving letrozole 
and 25 receiving placebo) were deemed ineligible for the follow-
ing reasons: improper duration of time on ( n = 7) or off ( n = 7) 
adjuvant tamoxifen, premenopausal status ( n = 6), prior recur-
rence ( n = 12), prior or concurrent malignancy ( n = 2),  inadequate 
primary surgery ( n = 2), hormone receptor – negative tumor ( n = 6), 
inadequate baseline investigation ( n = 3),  simultaneous  hormone 
therapy ( n = 3), or other concomitant medication ( n = 2). Thirty-
three patients (22 receiving letrozole and 11 receiving  placebo) 
had major protocol violations during the study. All 50 ineligible 
patients and the 33 patients with major protocol violations were 
included in the analyses.  Twenty-one patients (7 in the letrozole 
arm and 14 in the placebo arm) never received study medication 
and were excluded from the safety analyses. Five  patients who 
had been randomly assigned to letrozole received placebo, and 
one who had been assigned to placebo received  letrozole. These 
patients were included in the safety analyses but in the treatment 
group to which they crossed over; therefore, the safety analyses 
included 5149 patients (2572 receiving  letrozole and 2577 receiv-
ing placebo). The median follow-up of patients was 30 months, 
and the range was 1.5 to 61.4 months. The two treatment arms 
appeared balanced in terms of baseline  pretreatment characteris-
tics, tumor characteristics, and prior therapy for breast cancer 
( Table 1 ). The median time between  initial diagnosis of breast 
cancer and random  assignment in this study was 64.3 months 
(range 0.1 to 204 months). 
 The initial analysis of the MA.17 trial  ( 20 ) , which was pub-
lished in October 2003, was based on data received by August 
2003. That analysis included 207 breast cancer events, 73 deaths, 
384 patients followed for 40 months, and a median follow-up of 
2.4 years. This fi nal analysis, updated to the time of unblinding 
 (October 9, 2003) includes 247 breast cancer events; 113 deaths; 
1115 and 503 patients followed for 40 and 48 months, respec-
tively; and a median follow-up of 2.5 years. 
 Disease-Free Survival 
 Among the 247 events observed for the disease-free survival 
analysis, 92 occurred in women in the letrozole arm of the trial and 
155 occurred in women in the placebo arm. The sites of  recurrence 
are summarized in  Table 2 . The Kaplan – Meier curves for disease-
free survival are presented in  Fig. 2 for the two treatment groups. 
The 4-year disease-free survival for patients receiving  letrozole 
was 94.4% and for patients receiving placebo was 89.8%, repre-
senting an absolute reduction in recurrence of 4.6% for patients 
receiving letrozole. The stratifi ed log-rank test for the difference in 
disease-free survival, adjusting for receptor status, lymph node sta-
tus, and prior adjuvant treatment at random  assignment, yielded 
 P <.001. The hazard ratio for recurrence or contralateral breast can-
cer in those receiving letrozole relative to those receiving placebo 
was 0.58 (95% CI = 0.45 to 0.76), a relative reduction in risk of 
disease recurrence of 42% for women receiving letrozole. The 
treatment effect remained statistically signifi cant after adjustment 
for two additional potential prognostic factors in a stratifi ed Cox 
model — menopausal status at the start of tamoxifen treatment and 
duration of tamoxifen treatment (adjusted HR = 0.59; 95% CI = 
0.45 to 0.76). Prespecifi ed  subgroup analyses ( Fig. 3 ) showed that 
letrozole was superior to placebo in almost all of the subgroups, 
except for the subgroups of patients with unknown hormone recep-
tor status and those with unknown lymph node status, both of 
which contained very few patients. 
 Fig. 1.  CONSORT trial fl ow diagram for MA.17 trial. 
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 Letrozole also led to a statistically signifi cant improvement 
in distant disease – free survival: there was a 40% reduction in 
risk of distant recurrence in the letrozole group as compared 
with the placebo group (HR = 0.60, 95% CI = 0.43 to 0.84, 
 P = .002) ( Fig. 4 ). 
 Contralateral Breast Cancer Incidence 
 The annual incidence rate of contralateral breast cancer, per 
1000 patients, was 4.8 for those receiving placebo and 3.0 for 
those receiving letrozole (difference = 1.8 per 1000, 95% CI = 
 − 1.3 to 4.9 per 1000). Comparison of time-to-contralateral breast 
cancer curves ( Fig. 5 ) showed a 37.5% relative risk reduction 
with letrozole that was not statistically signifi cant (HR = 0.63, 
95% CI = 0.18 to 2.21,  P = .12). 
 Overall Survival 
 A total of 113 patients had died at the time of unblinding (51 
in the letrozole arm and 62 in the placebo arm). Of these, breast 
cancer was the cause of death for 16 patients in the letrozole arm 
and 22 in the placebo arm, a combination of breast cancer and 
nonprotocol treatment complication was the cause of one death 
in each arm, other primary malignancies were the cause of nine 
deaths in the letrozole arm and 11 in the placebo arm, other con-
ditions or circumstances were the cause of 24 deaths in the letro-
zole arm and 28 in the placebo arm, and one death in the letrozole 
arm was due to unknown causes. Four-year overall survival was 
 Table 2.  Summary of sites of events in the analysis of disease-free survival 
  Letrozole,  Placebo, 
 Event  no. (%)  no. (%) 
 All patients  2583 (100)  2587 (100) 
 Any event  92 (3.6)  155 (6.0) 
 Recurrence  75  127 
  Local breast recurrence only  9  22 
  Local chest well recurrence only  2  8 
  Regional recurrence only  7  3 
  Distant recurrence only *  52  82 
   Bone marrow  4  6 
   Lungs  11  20 
   Bone  37  55 
   Pleural effusion  1  10 
   Liver  16  15 
   Central nervous system  0  2 
   Other  13  21 
  Multiple sites of recurrence  5  12 
 Contralateral breast cancer only  17  28 
 * Patients may have had more than one site of recurrence. 
 Table 1.  Pretreatment characteristics at baseline * for all patients randomly 
assigned to letrozole or placebo in MA.17 
 Characteristic  Letrozole, no. (%)  Placebo, no. (%) 
 All patients  2583 (100)  2587 (100) 
 Race   
  White  2339 (90.6)  2369 (91.6) 
  Black  86 (3.3)  93 (3.6) 
  Other  117 (4.5)  87 (3.4) 
  Unknown  27 (1.0)  17 (0.7) 
  Missing  14 (0.5)  21 (0.8) 
 Age, years   
  <70  1901 (73.6)  1946 (75.2) 
  ≥ 70  682 (26.4)  641 (24.8) 
  Median  62 years  62 years 
 Menopausal status †   
  Postmenopausal   1964 (76.0)  1961 (75.8) 
  (i.e.,  ≥ 50 years of age)
  Postmenopausal but   179 (6.9)  144 (5.6) 
  <50 years of age ‡ 
  Postmenopausal (<50 years   92 (3.6)  101 (3.9) 
  of age, underwent bilateral 
  oophorectomy)
  Postmenopausal (<50 years    332 (12.9)  364 (14.1) 
  of age, became amenorrheic)
  Postmenopausal levels of   14 (0.5)  15 (0.6) 
  luteinizing hormone or follicle-
  stimulating hormone at random 
  assignment
  Missing  2 (0.1)  2 (0.1) 
 Axillary lymph node status   
  Negative  1292 (50.0)  1276 (49.3) 
  Positive  1171 (45.3)  1189 (46.0) 
  Unknown  113 (4.4)  113 (4.4) 
  Missing  7 (0.3)  9 (0.3) 
 Hormone receptor status §   
  Positive  2516 (97.4)  2519 (97.4) 
  Negative  2 (0.1)  6 (0.2) 
  Unknown  45 (1.7)  46 (1.8) 
  Missing  20 (0.8)  16 (0.6) 
 Duration of tamoxifen treatment   
  ≤ 5 years  1160 (44.9)  1208 (46.7) 
  >5 years  1420 (55.0)  1374 (53.1) 
  Median  5.0  5.0 
  Missing  3 (0.1)  5 (0.2) 
 Prior adjuvant chemotherapy   
  No  1402 (54.3)  1418 (54.8) 
  Yes  1177 (45.6)  1166 (45.1) 
  Missing  4 (0.2)  3 (0.1) 
 Prior surgery   
  Lumpectomy or segmental   1482 (57.4)  1499 (57.9) 
  mastectomy
  Mastectomy  1328 (51.4)  1334 (51.6) 
  Axillary node dissection  2474 (95.8)  2479 (95.8) 
 * Baseline refers to assessments made at the time of the randomization. 
 † At the start of adjuvant tamoxifen treatment. 
 ‡ Women were considered postmenopausal as defi ned in the  “ Subjects and 
Methods ” section. 
 § Positive refers to positivity for the estrogen receptor, progesterone receptor, 
or both. 
 Fig. 2. Kaplan – Meier curves for disease-free survival. An event is defi ned 
as recurrence of breast cancer (breast, chest wall, regional nodes, or distant 
metastasis) or a contralateral breast cancer (whichever occurs fi rst). N = number 
at risk; S = survival percent, with 95% confi dence intervals in parentheses. 
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95.4% for patients receiving letrozole and 95.0% for patients 
 receiving placebo, an absolute increase of 0.4%. Kaplan – Meier 
analysis ( Fig. 6 ) showed a reduced risk of death in the letrozole 
arm compared with the placebo arm, but the difference was not 
statistically signifi cant (HR of death from any cause = 0.82, 95% 
CI = 0.57 to 1.19, stratifi ed log-rank  P = .3). The results of 
 prespecifi ed subgroup analyses ( Fig. 7 ) revealed that letrozole 
was associated with statistically signifi cant improvements in 
overall survival, compared with placebo, both in node-positive 
patients (HR = 0.61, 95% CI = 0.38 to 0.98,  P = .04) and in pa-
tients who had taken tamoxifen for more than 5 years (HR = 0.56, 
95% CI = 0.33 to 0.97,  P = .04). 
 Treatment Discontinuation and Toxicity 
 There were three major reasons for patients discontinuing 
 protocol treatment: patient refusal (11.4% of the patients receiv-
ing letrozole and 11.1% of those receiving placebo,  P = .79), tox-
icity (4.9% of the patients receiving letrozole and 3.6% of those 
receiving placebo,  P = .019), and  “ other reasons ” (3.8% of the 
patients receiving letrozole and 4.7% of those receiving placebo, 
 P = .097).  Table 3 shows toxicities for which there was more than 
1 percentage point difference between the two treatment groups 
or an incidence rate greater than or equal to 5% in either arm 
 during the protocol treatment. Hot fl ashes, anorexia,  arthralgia, 
myalgia, and alopecia were all statistically signifi cantly more 
common in those receiving letrozole, and vaginal bleeding was 
statistically signifi cantly more common in those  receiving pla-
cebo. Additional specifi c toxicities related to bone metabolism 
and cardiovascular disease are shown in  Table 4 . More patients 
receiving letrozole had a fracture, a new diagnosis of osteoporo-
sis, or cardiovascular disease on study, but only the incidence 
of self-reported new osteoporosis was statistically  signifi cantly 
different between the two arms. Diagnoses of new osteoporosis 
were reported by 364 patients, 209 (8.1%) of those receiving 
 letrozole and 155 (6.0%) of those receiving placebo ( P = .003), 
with median times to occurrence of 0.70 years for those receiving 
letrozole and 0.52 years for those receiving  placebo. Of a total of 
256 patients who experienced a clinical fracture during the study 
period, 137 (5.3%) were taking letrozole and 119 (4.6%) were 
taking placebo ( P = .25). Median time from random assignment 
to a new bone fracture was 1.06 years for those taking letrozole 
and 0.86 years for those taking placebo. Cardiovascular events 
were observed in 149 (5.8%) and 144 (5.6%) of patients in the 
letrozole and placebo arms, respectively ( P = .76). 
 Finally, we analyzed the occurrence of other malignancies 
in the two arms. Four patients who received letrozole and 11 
who received placebo developed endometrial cancer ( P = .12); 
no  differences were observed in the incidence of any other 
 malignancies. 
 D ISCUSSION 
 Despite the benefi ts of 5 years of adjuvant tamoxifen, more 
than 50% of breast cancer relapses and more than two-thirds of 
deaths occur after the initial 5 years after surgery  ( 2 , 3 ) . These 
recurrences are predominantly distant visceral and skeletal 
 metastases, whatever the patient’s initial lymph node status. 
 Fig. 3.  Forest plots of the treatment effect (letrozole 
versus placebo), in terms of disease-free survival, in 
subgroups defi ned by hormone receptor status, lymph 
node status, previous chemotherapy, menopausal criteria, 
and duration of tamoxifen treatment. For each subgroup, 
the hazard ratio for recurrence or contralateral breast 
cancer is plotted as a  solid square, and the area of the 
square is proportional to the variance of the estimated 
effect. The length of the horizontal line through the 
square indicates the 95% confi dence interval (CI). The 
 arrow at the end of the horizontal line indicates that 
the confi dence interval is larger than the scale of the 
fi gure. 
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 Fig. 4. Kaplan – Meier curves for distant recurrence – free survival. Any distant 
metastasis is defi ned as an event. N = number at risk; S = survival percent, with 
95% confi dence intervals in parentheses. 
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acceptable endpoint of both Food and Drug Administration and 
National Cancer Institute trials of endocrine therapy in the adju-
vant setting. We feel that it is the appropriate primary endpoint 
for trials of well-tolerated anticancer endocrine therapies, such as 
this trial, for two major reasons. First, accumulated experience 
from studies of other endocrine therapies, including oophorec-
tomy and tamoxifen, suggests that disease-free survival is a 
 surrogate for overall survival  ( 2 , 3 ) . Second, preventing breast 
cancer recurrence is, of itself, important because women with 
distant metastases inevitably die of breast cancer; moreover, 
 because recurrences can have adverse psychological effects, 
 preventing recurrence is important for psychological reasons as 
well. Women who suffer an in-breast recurrence often require the 
 mastectomy that their initial management was intended to 
avoid, and women who develop new breast cancer repeat the 
trauma of their initial diagnosis and treatment. Indeed, the psy-
chological morbidity of a second breast cancer event has been 
shown to have a greater impact on women than their fi rst diag-
nosis  ( 24 – 27 ) . The importance of preventing breast cancer 
 recurrences is also underscored by the rate of these events in our 
study. In the placebo arm of MA.17, the event rate in lymph 
node – negative women was  approximately 2% per year and in 
lymph node – positive women was 4% per year, indicating an 
 ongoing and substantial rate of late recurrences that did not 
 decrease over the study period and is comparable to that seen in 
both the Oxford overview  ( 2 – 4 ) and in  reports by others  ( 8 ) . 
 Since our initial publication, it has been suggested that MA.17 
was unblinded prematurely because of the stopping rules related 
to overall disease-free survival and that a statistically signifi cant 
improvement in distant disease – free survival would have been a 
more meaningful endpoint  ( 28 ) . Our updated analysis indicates 
that letrozole treatment did result in a statistically signifi cant 
 improvement in distant disease – free survival ( P = .002). 
 Our prespecifi ed subset analyses indicate that letrozole use 
was also associated with a statistically signifi cant improvement 
in overall survival among women with positive axillary lymph 
nodes. Although subgroup analyses have some limitations —
 including, for example, multiple comparison issues — these 
 analyses provide what is, to our knowledge, the fi rst suggestion 
of a survival advantage obtained with the use of any aromatase 
inhibitor in early-stage breast cancer and also the fi rst suggestion 
that extending adjuvant endocrine therapy beyond 5 years of 
tamoxifen can afford a survival advantage. The reduction in the 
risk of overall recurrence was greater for lymph node – negative 
patients (55%) than for lymph node – positive patients (39%) 
( Fig. 3 ), although the reduction in the risk of recurrence with 
 letrozole in lymph node – negative women did not translate 
into an improvement in overall survival (HR of death from any 
cause = 1.52, 95% CI = 0.76 to 3.06;  Fig. 7 ). 
 All-cause mortality, as well as breast cancer – specifi c mortal-
ity, is important when offering adjuvant therapy to relatively 
healthy elderly women. Among 33 deaths in women with lymph 
node – negative disease (20 receiving letrozole and 13 receiving 
placebo), there were 17 non – breast cancer deaths in women 
 receiving letrozole (fi ve cardiovascular, two fatal strokes, fi ve 
second malignancies, and fi ve other) and 11 in women receiving 
placebo (fi ve cardiovascular, one fatal stroke, two second malig-
nancies, and three other). A review, blinded to treatment alloca-
tion, of the medical information submitted as supporting 
documentation for the cause of death among the 33 women 
with lymph node – negative disease found no probable causal 
We demonstrated a statistically signifi cant improvement in 
 disease-free survival for women taking letrozole after standard 
adjuvant tamoxifen, with substantial reductions in local, distant, 
and  contralateral events, and an improvement in overall survival 
in women with lymph node – positive disease. At the outset of the 
trial, we anticipated that additional genetic changes would have 
occurred when primary breast tumors metastasize to the micro-
metastatic environment and that this progressive genetic insta-
bility at the site of metastases would be refl ected in lower 
proportional reductions in distant disease recurrence than in 
 local recurrence. However, we found that distant micrometasta-
ses that have survived 5 years of tamoxifen therapy appear to 
remain highly estrogen sensitive and responsive to extended 
 adjuvant letrozole treatment and, therefore, to be as preventable 
as early in-breast or locoregional lesions. 
 Although we did not observe an increase in overall survival, it 
should be noted that disease-free survival has historically been an 
 Fig. 5.  Cumulative hazard curves for contralateral breast cancer – free survival. 
Development of contralateral breast cancer is defi ned as an event. N = number 
at risk; H = cumulative hazard rate per 1000, with 95% confi dence intervals in 
parentheses. 
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 relationship between these deaths and letrozole. In addition, there 
was no excess of non – breast cancer deaths in women on the 
 letrozole arm as compared with women on the placebo arm in 
the study overall, and no reason to think that nodal status should 
be related to the risk of intercurrent deaths. 
 Although letrozole was associated with statistically signifi -
cantly improved disease-free survival in women who had taken 
tamoxifen both for more or less than 5 years, an apparent overall 
survival advantage with letrozole was seen only in those who 
had taken tamoxifen for more than 5 years. This difference may 
 refl ect the inherently better prognosis and slower growth of 
 tumors among women who took tamoxifen for longer or may 
suggest that longer duration of tamoxifen-resistant or -dependent 
disease is more vulnerable to the benefi ts achieved with subse-
quent letrozole. The question of the optimal duration of initial 
tamoxifen treatment is of major interest given the recent report of 
Coombes et al.  ( 29 ) , who showed that switching to exemestane 
after 2 – 3 years of tamoxifen treatment is superior in terms of 
disease-free recurrence than staying on tamoxifen for a full 5 
years. Thus, since the original publication of MA.17 switching to 
an aromatase inhibitor after 5 years, or after 2 – 3 years, of prior 
tamoxifen treatment have both become choices in the clinic. 
 Favors Letrozole  Favors Placebo
hazard ratioSubgroup (No.) 95% CI
Receptor Positive (5035) 
Receptor Unknown (91)
Negative (2568)
Positive (2360)
Unknown (226)
Yes (2343)
No (2820)
Other (1241)
< 5 years  (2368)
> 5 years  (2794)
0.2 0.5 1 2 5
Duration of Tamoxifen
>  50 at start of Tamoxifen (3925)
Menopausal Criteria
Previous Chemotherapy
Nodal Status
Hormone Receptor Status
 Fig. 7. Forest plots of the treatment effect (letrozole 
versus placebo), in terms of overall survival, in 
subgroups defi ned by hormone receptor status, lymph 
node status, previous chemotherapy, menopausal 
criteria, and duration of tamoxifen treatment. For each 
subgroup, the hazard ratio for death from any cause is 
plotted as a  solid square, and the area of the square is 
proportional to the variance of the estimated effect. The 
length of the horizontal line through the square indicates 
the 95% confi dence interval (CI). The  arrow at the 
end of the horizontal line indicates that the confi dence 
interval is larger than the scale of the fi gure. 
 Table 3.  Acute toxicities reported by patients in MA.17 * 
  Letrozole ( N = 2572)  Placebo ( N = 2577) 
 Toxicity  Grade 1  Grade 2  Grade 3  Grade 4  Total, no. (%)  Grade 1  Grade 2  Grade 3  Grade 4  Total, no. (%)  P value † 
 Edema  470  96  5   571 (22)  428  110  3  1  542 (21)  .31 
 Hypertension  54  21  55   130 (5)  48  13  68   129 (5)  .94 
 Hot fl ashes/fl ushes  823  661  2   1486 (58)  782  601    1383 (54)  .003 
 Fatigue  801  183  14  1  999 (39)  795  195  7  1  998 (39)  .95 
 Sweating  551  231    782 (30)  543  217    760 (29)  .48 
 Anorexia  115  26  1   142 (6)  87  19  3  1  110 (4)  .039 
 Constipation  297  60  6   363 (14)  313  66  3   382 (15)  .48 
 Diarrhea  125  29  14   168 (7)  140  26  10   176 (7)  .69 
 Nausea  267  35  6   308 (12)  267  38  9   314 (12)  .83 
 Vaginal bleeding  121  22  2   145 (6)  141  50  3  2  196 (8)  .005 
 Infection without   34  63  27   124 (5)  35  62  13  2  112 (4)  .42 
 neutropenia
 Arthritis  110  46  10  1  167 (6)  92  41  4   137 (5)  .07 
 Hypercholesterolemia  379  37  2   418 (16)  357  48  6   411 (16)  .79 
 Dizziness  386  59  13   458 (18)  383  51  6  1  441 (17)  .53 
 Insomnia  119  45  2   166 (6)  103  30  2   135 (5)  .06 
 Depression  85  42  14  2  143 (6)  74  49  7  1  131 (5)  .45 
 Headache  546  138  22   706 (27)  519  140  25  1  685 (27)  .49 
 Arthralgia  381  245  25   651 (25)  338  172  22   532 (21)  < .001 
 Myalgia  241  121  18   380 (15)  211  88  11   310 (12)  .004 
 Bone pain  81  46  13  1  141 (5)  92  44  12  1  149 (6)  .67 
 Dyspnea   143  14  4  161 (6)   142  18  3  163 (6)  .95 
 Alopecia  114  12    126 (5)  84  5    89 (3)  .01 
 Vaginal dryness  75  72    147 (6)  60  69    129 (5)  .26 
 * Only toxicities that affected more than 5% of subjects or that differed by more than 1 percentage points between arms are shown. Toxicities were graded according 
to Common Toxicity Criteria Version 2.0. Empty cells indicate that the toxicity was not observed. 
 † P values are from Fisher’s exact test. 
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 It is known that aromatase inhibitors do not fully suppress 
 estrogen production in premenopausal women and may induce 
ovulation and result in an ovarian hyperstimulation syndrome 
 ( 30 , 31 ) . Consequently, we recommend that aromatase inhibitors 
not be used as monotherapy in premenopausal women. Because 
a proportion of women who are younger than 50 years of age at 
diagnosis may regain ovarian function during or after tamoxifen 
cessation, women being considered for letrozole treatment should 
meet stringent criteria for being postmenopausal. Because the 
outcome of women in our trial was not affected by our defi nition 
of menopause, it would be appropriate to use the criteria defi ned 
in our study when applying the results in clinical practice. 
 The value of adjuvant aromatase inhibitors in women who had 
received prior chemotherapy has been questioned since the initial 
report of the ATAC (Arimidex, tamoxifen, alone or in combina-
tion) trial failed to show a benefi t of anastrozole in women who 
had received prior adjuvant chemotherapy  ( 32 ) . In our trial of 
post-tamoxifen treatment, letrozole was equally  effective in women 
who had or had not received prior adjuvant chemotherapy. 
 Letrozole was extremely well tolerated in the MA.17 trial. Hot 
fl ashes, myalgia, arthralgia, and alopecia — all of which differed 
between the trial arms — are probably related to  depleted estrogen 
levels. However, the role of estrogen in the incidence of arthralgia 
and arthritis in menopause generally is controversial, and symp-
toms of myalgia and arthralgia appeared promptly in many women 
receiving letrozole, leaving their etiology  unclear. More rigorous 
evaluation of these symptoms to  distinguish arthralgia from 
 arthritis and myalgia would be desirable in future trials. Although 
alopecia was more common in women receiving letrozole than in 
women receiving placebo, it was  generally mild and of minimal, 
if any, cosmetic signifi cance. 
 Of importance, no excess of urogenital symptoms was  reported 
by women receiving letrozole. Women enrolled on MA.17 had 
recently completed 5 years of tamoxifen, which is associated 
with an increased risk of vaginal bleeding  ( 2 – 4 ) . It is therefore of 
note that vaginal bleeding was more common in women receiv-
ing placebo than in women receiving letrozole. This difference 
may refl ect inhibition of endometrial proliferation by the aroma-
tase inhibitor. Indeed, Garrone et al.  ( 33 ) found that endometrial 
thickness is reduced more rapidly after tamoxifen by administer-
ing an aromatase inhibitor than by simply stopping tamoxifen. 
The absence of endometrial stimulation has also been demon-
strated for anastrozole in the ATAC endometrial substudy  ( 34 ) . 
A phase II trial of letrozole in advanced endometrial cancer has 
 further described the antiproliferative effects of this agent  ( 35 ) . 
 Letrozole was associated with a statistically signifi cant in-
crease in newly diagnosed osteoporosis but only with a non –
 statistically signifi cant increase in clinical fractures. These 
fi ndings are compatible with the known increase in bone resorp-
tion associated with aromatase inhibitor – induced estrogen deple-
tion  ( 36 ) . Of importance, however, is the fact that a loss of bone 
 mineral density over the 5 years of MA.17 in women assigned to 
letrozole may be offset in part by the benefi t experienced from 
tamoxifen during the preceding 5 years. The latter was demon-
strated in the bone substudy of the ATAC trial  ( 37 ) . Because 
 decreases in bone mineral density can be monitored and treated, 
the important improvements in cancer outcome achieved by ex-
tended adjuvant letrozole should not be outweighed by excessive 
concern about bone loss. All patients enrolled on the MA.17 trial 
will continue to be followed with respect to new diagnoses of 
osteoporosis and clinical fractures. In the interim, women given 
extended adjuvant letrozole therapy should be advised to take 
calcium and vitamin D as per osteoporosis guidelines and to fol-
low recommendations for bone health, including regular moni-
toring of their bone mineral density, as suggested by an expert 
panel of the American Society of Clinical Oncology  ( 38 ) . 
 The optimal duration of adjuvant tamoxifen remains contro-
versial. In the National Surgical Adjuvant Breast and Bowel 
Project B-14 trial  ( 5 , 6 ) , the Scottish trial  ( 39 ) , and the ECOG 
 ( 40 ) trial, women completing their initial 5 years of adjuvant 
tamoxifen were randomly assigned to a further 5 years of tamox-
ifen or placebo. In addition, the French Breast Cancer Group  ( 41 ) 
randomly assigned patients late in follow-up who had not taken 
initial tamoxifen to adjuvant tamoxifen or not, starting 2 – 6 years 
after diagnosis. MA.17 is unique in that patients were randomly 
assigned to a novel agent after initial adjuvant therapy, thus 
 extending the duration of the adjuvant treatment period beyond 
5 years. MA.17 is also the fi rst double-blind, placebo-controlled 
trial of an aromatase inhibitor in early breast cancer, allowing a 
true assessment of toxicities. However, it should be borne in 
mind that all participants received 5 years of prior tamoxifen, 
which could infl uence end-organ and other toxic effects, such as 
bone metabolism and cardiovascular risk. This extended infl u-
ence is a particular concern because tamoxifen has a long plasma 
and tissue half-life  ( 42 , 43 ) . 
 This study shows that extended adjuvant letrozole given for 5 
years after tamoxifen reduces the risk of breast cancer recurrence 
 Table 4.  Bone and cardiovascular toxicities, adverse events, and intercurrent 
illnesses in patients on MA.17 * 
  Letrozole,   Placebo,   
 Event  no. (%)  no. (%)  P value† 
 All patients  2572   2577  
 Clinical bone fractures    
  Yes  137 (5.3)  119 (4.6)  .25 
  No  2424 (94.2)  2446 (94.9)  
  Missing  11 (0.4)  12 (0.5)  
 Location of bone fracture    
  Spinal  15 (0.6)  10 (0.4)  
  Wrist  33 (1.3)  22 (0.9)  
  Pelvis  5 (0.2)  4 (0.2)  
  Hip  5 (0.2)  8 (0.3)  
  Femur  3 (0.1)  2 (0.1)  
  Tibia  6 (0.2)  2 (0.1)  
  Ankle  13 (0.5)  11 (0.4)  
  Other  75 (2.9)  69 (2.7)  
 New osteoporosis    
  Yes  209 (8.1)  155 (6.0)  .003 
  No  2352 (91.4)  2410 (93.5)  
  Missing  11 (0.4)  12 (0.5)  
 Cardiovascular disease    
  Yes  149 (5.8)  144 (5.6)  .76 
  No  2412 (93.8)  2421 (93.9)  
  Missing  11 (0.4)  12 (0.5)  
 Type of cardiovascular disease    
  Myocardial infarction  9 (0.3)  11 (0.4)  
  Stroke/transient ischemic   17 (0.7)  15 (0.6)  
  attack
  New or worsening angina  31 (1.2)  23 (0.9)  
  Angina requiring PTCA  3 (0.1)  7 (0.3)  
  Angina requiring CABG  5 (0.2)  12 (0.5)  
  Thromboembolic event  11 (0.4)  6 (0.2)  
  Other  100 (3.9)  95 (3.7)  
 * A patient may have more than one type of fracture or cardiovascular disease. 
PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary 
 artery bypass graft. 
 † P values are from Fisher’s exact test. 
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and may be associated with an improvement in overall survival 
in women with lymph node – positive disease. Letrozole was well 
tolerated, and the patients were highly compliant. An extension 
to MA.17, randomly assigning patients to a further 5 years of le-
trozole versus placebo, is under way. This extension of MA.17 
will allow a better determination of the optimal duration of treat-
ment both for effi cacy and long-term toxicities. 
 The MA.17 trial results have changed clinical practice, but 
because the median follow-up was short the question of duration 
of therapy remains unanswered for the time being. In addition, it 
is uncertain from the results whether women should be offered 
extended adjuvant therapy with letrozole if more than 3 months 
have elapsed since cessation of tamoxifen treatment. A reanalysis 
of the entire study after unblinding, including those patients who 
switched to letrozole after variable times of taking placebo, will 
address this question. Chronic toxicity assessment, although cur-
rently limited, will be further addressed by ongoing follow-up of 
all MA.17 participants and by the extension of MA.17. 
 In summary, this fi nal analysis of unblinded data confi rms our 
earlier fi nding  ( 20 ) of a substantial reduction in risk of recurrence 
and excellent tolerability with extended adjuvant letrozole. The 
fi ndings of a distant disease – free survival advantage with letro-
zole and an apparent overall survival advantage in women pre-
senting with metastasis to the lymph nodes are particularly 
noteworthy. The American Society of Clinical Oncology Tech-
nology Assessment Committee has recently recommended the 
use of an aromatase inhibitor as initial therapy or in sequence 
with tamoxifen as appropriate treatment for postmenopausal 
 receptor-positive early-stage breast cancer  ( 44 ) . Our results sup-
port these recommendations. Adjuvant letrozole should be 
discussed with all postmenopausal women completing standard 
adjuvant tamoxifen therapy. 
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